The Braak staging system is a neuropathological classification scheme that describes the progressive spread of neurofibrillary tau pathology in the brain across Alzheimer's disease (AD) and other tauopathies. Developed by Heiko and Eva Braak, this system is based on the topographical distribution of neurofibrillary tangles (NFTs) and is one of the core neuropathological criteria for AD diagnosis[^1].
Neurofibrillary pathology progresses through six sequential stages:
- Pathology confined to the transentorhinal and perirhinal cortex
- Clinically: Preclinical or very early AD
- Minimal cognitive impairment
- Spread to the hippocampus, entorhinal cortex, and amygdala
- Clinically: Early to moderate AD
- Memory impairment becomes evident
- Widespread involvement of the neocortex
- Clinically: Moderate to severe AD
- Significant cognitive decline
The Braak staging reflects the characteristic pattern of tau propagation in AD:
- Origin: Pathology begins in the transentorhinal region (entry zone to the hippocampal formation)
- Spread: Progresses along anatomically connected pathways
- Hierarchy: Follows a predictable pattern from entorhinal cortex → hippocampus → limbic system → isocortex
The Braak stage correlates with:
- Cognitive impairment: Higher stages associated with greater dementia severity
- Memory dysfunction: Early stages particularly affect episodic memory
- Disease progression: Stages provide a framework for understanding disease progression
¶ PET Imaging and Braak Stages
In vivo tau PET imaging has enabled assessment of Braak-like patterns in living patients[2][3]:
- [18F]flortaucipir PET shows binding patterns that recapitulate Braak stages
- SUVR (Standardized Uptake Value Ratio) measurements correlate with postmortem staging
- Limitations: Early stages (I-II) may not be reliably detected by current tracers
Braak staging is related to other AD pathological features:
- Amyloid-beta: Amyloid deposition follows a different pattern but is necessary for AD diagnosis
- Neuritic plaques: CERAD scoring system complements Braak staging
- Clinical syndrome: The relationship between pathology and clinical symptoms is complex
¶ Importance in Research and Diagnosis
The Braak stage is a standard component of AD neuropathological assessment:
- Diagnostic criterion: One of the ABC criteria for AD neuropathology
- Staging system: Provides standardized disease severity measure
- Research applications: Enables comparison across studies
- Biomarker validation: PET and CSF tau markers validated against Braak stages
- Clinical trials: Endpoints often target tau pathology reduction
- Epidemiological studies: Correlating risk factors with pathology burden
- Interindividual variability: Some patients show atypical patterns
- PET resolution: Early stages difficult to detect with current PET tracers
- Other tauopathies: Progressive supranuclear palsy and corticobasal degeneration show different patterns
- Antemortem vs postmortem: Correlations between antemortem PET and postmortem staging are imperfect
- Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of tau pathology
- Regional tau deposition measured by [18F]THK5317 positron emission tomography
- Staging system for neurofibrillary tangle pathology and tau PET imaging
- Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration